LordsMed, the healthcare division of Lord’s Mark Industries Ltd has announced a revolutionary line of bio-chemistry reagents designed to transform diagnostic interventions for critical diseases. These reagents, boasting 99.7 percent accuracy and a shelf-life of 24 months, set a new standard in sensitivity and reliability.
The launch encompasses 10 world-class re-agents targeting essential biomarkers including Triglycerides, Uric Acid, Alkaline Phosphatase, and more. These products, patented in India, promise to fortify preventive healthcare mechanisms against prevalent illnesses. LordsMed intends to leverage its extensive Pan-India distribution network, comprising over 300 dealers, to make these re-agents widely accessible. Furthermore, the company plans to expand its reach to SAARC, African, and Eastern European markets, tapping into burgeoning global demand.
Sachidanand Upadhyay, MD of Lord’s Mark Industries Ltd, highlighted the significance of these advancements, stating, “Our re-agents with unmatched accuracy and sensitivity will redefine diagnostic standards for critical diseases.” Upadhyay emphasized the global potential of the patented re-agents, backed by India’s renowned patent recognition.
